Your browser doesn't support javascript.
loading
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients.
Del Re, M; Omarini, C; Diodati, L; Palleschi, M; Meattini, I; Crucitta, S; Lorenzini, G; Isca, C; Fontana, A; Livi, L; Piacentini, F; Fogli, S; De Giorgi, U; Danesi, R.
Affiliation
  • Del Re M; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
  • Omarini C; Division of Medical Oncology, University Hospital of Modena, Modena, Italy.
  • Diodati L; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Palleschi M; Unit of Medical Oncology, IRCCS-Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
  • Meattini I; Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy; Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
  • Crucitta S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
  • Lorenzini G; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Isca C; Division of Medical Oncology, University Hospital of Modena, Modena, Italy.
  • Fontana A; Unit of Medical Oncology, Department of Translational Research and New Technologies in Medicine, University of Pisa, Pisa, Italy.
  • Livi L; Department of Experimental and Clinical Biomedical Sciences 'M. Serio', University of Florence, Florence, Italy; Radiation Oncology Unit - Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy.
  • Piacentini F; Division of Medical Oncology, University Hospital of Modena, Modena, Italy.
  • Fogli S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
  • De Giorgi U; Unit of Medical Oncology, IRCCS-Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy.
  • Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy. Electronic address: romano.danesi@unipi.it.
ESMO Open ; 6(5): 100231, 2021 10.
Article in En | MEDLINE | ID: mdl-34509802
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Pharmaceutical Preparations Type of study: Observational_studies / Prognostic_studies Limits: Female / Humans Language: En Journal: ESMO Open Year: 2021 Document type: Article Affiliation country: Italy Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Pharmaceutical Preparations Type of study: Observational_studies / Prognostic_studies Limits: Female / Humans Language: En Journal: ESMO Open Year: 2021 Document type: Article Affiliation country: Italy Country of publication: United kingdom